# Sitagliptin in Renal Transplant Recipients

> **NCT00740363** · PHASE4 · COMPLETED · sponsor: **University of Oslo School of Pharmacy** · enrollment: 25 (actual)

## Conditions studied

- Glucose Intolerance

## Interventions

- **DRUG:** sitagliptin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00740363
- **Lead sponsor:** University of Oslo School of Pharmacy
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2012-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00740363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00740363, "Sitagliptin in Renal Transplant Recipients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00740363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*